Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cutaneous T Cell Lymphoma: early-phase trial registry
15 of 24 indexed Cutaneous T Cell Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #686 of 28,707 conditions by registered trial count.
24 US clinical trials · 15 currently recruiting · #686 of 28,707 conditions by registered trial count
Cutaneous T Cell Lymphoma: 24 US clinical trials tracked, 15 recruiting.
Cutaneous T Cell Lymphoma is the subject of 24 registered US clinical trials on ClinicalTrials.gov, 15 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most active sponsor is Northwestern University, running 2 of these trials.
Enrollment posture brief
Registry condition cutaneous-t-cell-lymphoma
OPEN 15 | RECR 63% | LATE 1 | EARLY 16 | RANK #686 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adolescent (63% recruiting · 16 trials)
Cutaneous T Cell Lymphoma lists 15 open slots (63% of 24 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cutaneous T Cell Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cutaneous T Cell Lymphoma is recruiting above its size-band peers.
15 of 24 indexed trials (62.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Cutaneous T Cell Lymphoma trials is spread across many organizations.
Northwestern University accounts for 2 of 24 trials (8.3%). 21 distinct sponsors appear on at least one study for this condition label.
-
Most Cutaneous T Cell Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 44 among the 24 trials that report a genuine target (sentinel values excluded). 19 of those (79.2%) plan for fewer than 100 participants.
-
Cutaneous T Cell Lymphoma research is mostly interventional.
19 interventional and 5 observational studies make up this index (79.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
24 total, page 1 of 1
Characterization of the Microbiome in Cutaneous T Cell Lymphoma
Northwestern University
NCT03932279
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
University of Pittsburgh
NCT00177268
Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
Kyowa Kirin
NCT04014374
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
Soligenix
NCT06470451
Photopheresis in Early-stage Mycosis Fungoides
Columbia University
NCT05680558
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
National Cancer Institute (NCI)
NCT07055477
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
SciTech Development
NCT04234048
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Jonathan Brammer
NCT07356245
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
UNC Lineberger Comprehensive Cancer Center
NCT06860880
Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
H. Lee Moffitt Cancer Center and Research Institute
NCT07047885
Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
University of Michigan Rogel Cancer Center
NCT05956041
A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma
Dana-Farber Cancer Institute
NCT04045470
A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides
Memorial Sloan Kettering Cancer Center
NCT05296304
A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA
M.D. Anderson Cancer Center
NCT06698822
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
University of Alabama at Birmingham
NCT05414500
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
National Cancer Institute (NCI)
NCT00007345
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
Mundipharma Research Limited
NCT02576496
Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Acrotech Biopharma
NCT00554827
Long-term Use of Romidepsin in Patients With CTCL
Northwestern University
NCT02296398
Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.
Genmab
NCT00071071
A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma
Eli Lilly and Company
NCT00744991
Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma
Boston University
NCT00306969
Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)
Abramson Cancer Center at Penn Medicine
NCT01676831
Effect of Denileukin Diftitox on Immune System in CTCL Patients
University of Pittsburgh
NCT00254332
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 7 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Cutaneous T Cell Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cutaneous T Cell Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cutaneous T Cell Lymphoma page
24 registered trials, 15 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 15 Cutaneous T Cell Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Northwestern University sponsors the most Cutaneous T Cell Lymphoma trials on record, review their full trial history before evaluating a specific study. See Northwestern University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cutaneous T Cell Lymphoma condition card totals 24 registered trials; most-linked intervention Mogamulizumab; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.